Ablynx demonstrates nebulisation-robust RSV nanobody
This article was originally published in Scrip
Executive Summary
The completion of Ablynx' Phase I study with ALX-0171 marks a significant proof of concept for the pulmonary delivery of the company's nanobody technology. Ablynx said that Phase I data showed that the product, a trivalent molecule, could be administered "via nebulisation directly into the lung in a clinical trial setting, confirming its potential as a first-in-class therapy to treat respiratory syncytial virus (RSV) infections".